| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1500 |
| Trial ID | NCT02315612 |
| Disease | Acute Lymphoblastic Leukemia | Non-Hodgkin's Lymphoma | Follicular Lymphoma | Large B-Cell Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies |
| Year | 2014 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 150029|15-C-0029 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||